A Zantac Lawsuit Review


02 Jan


A Zantac Lawsuit is an individual legal claim for compensation by individuals who took the anti-emetics drug and subsequently were diagnosed with lung cancer. Zantac (as well as its generic variant ranitidine) was found to contain a carcinogenic element called acetaldehyde. This carcinogenic element is known to increase the rate of spread of cancer in various parts of the body, particularly the lungs, esophagus and gastrointestinal tract. As a direct consequence, Zantac users have significantly increased their chances of developing a form of lung cancer called pulmonary cell cancer or pneumoconiosis.


Zantac Lawsuit victims have filed lawsuits against GlaxoSmithKline, the manufacturer of Zantac, and generic drug manufacturer AstraZeneca, Inc. The manufacturers have strenuously denied that they are liable for the harms suffered by Zantac users. They maintain that the claims made in the Zantac Lawsuit are without merit and that there is no evidence that Zantac is defective. Despite this denial from the manufacturers, the plaintiffs have filed numerous lawsuits against the three claiming that the defendants failed to warn about the risks associated with their drugs and did not carry out adequate studies on the possible effects of prolonged use of Zantac.


While the manufacturers of Zantac argue that they have done everything possible to warn the public about the dangers of using Zantac, both the FDA and courts have rejected these claims. The FDA found that Zantac's warning about the possibility of developing cancer was inadequate and did not contain enough information to allow the drug to be safely used by patients. Likewise, a California Court found that AstraZeneca failed to warn its consumers of the risks associated with their prescription drug, maintaining that the manufacturer failed to develop enough evidence to indicate that the drug was safe.


As previously mentioned, the manufacturers of Zantac deny all responsibility and say that the lawsuits filed against them are based on 'baseless' allegations. However, plaintiffs in Zantac Lawsuit lawsuits have produced medical records that strongly suggest that Zantac may have been responsible for causing or accelerating certain types of cancers. Some of the lawsuits also state that Zantac was aware of the risks of its prescription drug and did nothing to warn its consumers. In one instance, a plaintiff in a Zantac Lawsuit brought suit claiming that her daughter died because of Zantac and the effects of its prescription drug on her daughter. A federal judge dismissed this claim, stating that there was insufficient evidence that Zantac caused the death of the child.


Individual-lawsuits can also be filed in a Zantac Lawsuit case. In these cases, the defendant (the company manufacturing Zantac) generally enters into a class action lawsuit with other plaintiffs who have similar complaints. Under these class-action lawsuits, individual plaintiffs are allowed to join as representatives of the class, with the goal of persuading a court to grant class-action status to their case. As in the case of Zantac Lawsuit, individual-lawsuit plaintiffs are granted due process rights, the right to representation by counsel, and are protected from abusive treatment by the defendant's attorneys. In some instances, individual-lawsuit plaintiffs have been able to successfully leverage a settlement offer to greatly reduce their monetary losses.
The Zantac Lawsuit is just one of many patent and trademark infringement lawsuits across the country, as companies rely on their own proprietary technology to keep their products exclusive. In recent years, generic versions of popular drugs have become widely available to the general public. Because patented pharmaceuticals are so expensive and hard to produce, generic versions of patented pharmaceuticals are often the only option available for many people. Click here for more info!

Learn more at https://www.britannica.com/science/ranitidine 

Comments
* The email will not be published on the website.
I BUILT MY SITE FOR FREE USING